Journal of Viral Hepatitis, Volume 32, Issue 11, November 2025.ABSTRACT Improved HCV diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. 253 HCV seropositive and 214 seronegative samples were tested, and
Diana R. Hardie +6 more
wiley +1 more source
Hepatitis C: global epidemiology and strategies for control [PDF]
, 2016 It is estimated that globally there are approximately 100 million persons with serological evidence of current or past HCV infection, and that HCV causes about 700 000 deaths each year.
Easterbrook, PJ +3 more
core
Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs
European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar +7 more
wiley +1 more source
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme [PDF]
, 2019 To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale‐up of treatment among people who inject drugs (PWID).
Ahmad, Farsana +9 more
core +5 more sources
Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs:A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol study [PDF]
, 2019 Introduction: Hepatitis c is a blood-borne virus (HCV) that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person.
Beer, Lewis J. Z. +8 more
core +2 more sources
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry [PDF]
, 2022 Yu Jun Wong +9 more
openalex +1 more source
Liver International, Volume 45, Issue 10, October 2025.ABSTRACT Background and Aims Advances in artificial intelligence, particularly large language models (LLMs), hold promise for transforming chronic disease management such as Hepatitis C Virus (HCV) infection. This study evaluates the impact of retrieval‐augmented generation (RAG) and supervised fine‐tuning (SFT) on both open‐ended question answering ...
Mauro Giuffrè +9 more
wiley +1 more source
Liver International, Volume 45, Issue 10, October 2025.ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella +30 more
wiley +1 more source
Revista da Sociedade Brasileira de Medicina Tropical, 2020 INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective.
Vinicius Lins Ferreira +3 more
doaj +1 more source
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]
, 2020 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F +20 more
core